Group 1 - Shida Shenghua expects a net loss of 52 million to 60 million yuan for the first half of 2025, a year-on-year decrease of 236.64% to 257.66% [1] - ST Zhizhi's vice president Wang Dong resigned for personal reasons, effective immediately upon delivery of the resignation to the board [1] - Haoyuan Pharmaceutical plans to increase capital by 400 million yuan to its wholly-owned subsidiary through a debt-to-equity swap, raising the registered capital from 400 million to 800 million yuan [1] Group 2 - Longxun Co. announced that shareholders and executives plan to reduce their holdings by up to 2% of the company's shares [2] - Aijian Group confirmed it has not engaged in any stablecoin-related business as of now [3] - Yanghe Co.'s chairman Zhang Liandong resigned due to work adjustments, effective immediately [5] Group 3 - Huanwei New Materials announced a stock suspension due to the major matter that may lead to a change in control [5] - Hualing Cable recently won contracts worth 456 million yuan in the power new energy sector, accounting for 10.97% of its audited revenue for 2024 [6] - Aerospace Changfeng plans to publicly transfer 55.45% of its stake in Aerospace Boke [6] Group 4 - Suzhou Planning is planning to acquire control of Dongjin Aerospace Technology, leading to a stock suspension for up to 10 trading days [6] - Yuexiu Capital intends to increase its stake in Yuexiu Real Estate using up to 204.22 million yuan through the Hong Kong Stock Connect [6] - Baichuan Co.'s actual controller and chairman Zheng Tiejiang is under investigation and has received a detention notice [7] Group 5 - XWANDA plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - ST Aowei reported a loss of approximately 25.04 million yuan in inventory due to poor storage by a third party [8] - Yian Technology plans to increase capital by 120 million yuan to its subsidiary, raising its equity stake from 60% to 72.973% [9] Group 6 - Dongli New Science's wholly-owned subsidiary was applied for bankruptcy reorganization by creditors due to insolvency [11] - Bochuang Technology changed its name to Changxin Bochuang Technology, effective July 2, 2025 [14] - Huayang Co.'s controlling shareholder received a notice of administrative penalty from the China Securities Regulatory Commission [15] Group 7 - Hangzhou Thermal Power's shareholders plan to reduce their holdings by up to 4.09% of the company's shares [16] - Guoke Military Industry's two shareholders plan to reduce their holdings by up to 1.81% of the company's shares [17] - Pangu Intelligent's seven shareholders plan to reduce their holdings by up to 1% of the company's shares [19]

证券研究报告：医药生物|行业周报 发布时间：2025-06-16 行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 7895.79 | | --- | --- | --- | | 52 | 周最高 | 8490.25 | | 52 周最低 | | 6070.89 | 行业相对指数表现 2024-06 2024-08 2024-11 2025-01 2025-04 2025-06 -14% -11% -8% -5% -2% 1% 4% 7% 10% 13% 16% 19% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:龙永茂 SAC 登记编号:S1340523110002 Email:longyongmao@cnpsec.com 近期研究报告 推荐标的：英科医疗、迈普医学、怡和嘉业、微电生理、 拱东医疗、派林生物、益丰药房、大参林、康臣药业、佐力药 业、桂林三金、天士力、新里程、美年健康、国际医学。 《政策支持上市公司通过并购重组高 质量发展，行业整合持 ...

银轮股份：拟设合资公司 发力具身智能机器人零部件市场 6月12日，银轮股份（002126）发布公告称，公司与苏州伟创电气科技股份有限公司、深圳市科达利实 业股份有限公司、上海开普勒机器人有限公司及深圳市伟立成长企业管理咨询合伙企业（有限合伙）签 订《合资设立公司协议》，共同出资设立苏州依智灵巧驱动科技有限公司。银轮股份拟投资1000万元， 持股比例为20%。此次投资旨在借助各方在具身智能机器人零部件领域的技术优势和市场资源，推动具 身智能机器人产业的快速发展。 资料显示，银轮股份成立于1999年3月，主营业务是油、水、气、冷媒间的热交换器、汽车空调等热管 理产品以及后处理排气系统相关产品的研发、生产与销售。 所属行业：基础化工–化学制品–其他化学制品 福建金森：董事长应飚离任 6月12日，福建金森（002679）发布公告称，公司董事、董事长（法定代表人）应飚因工作原因提交书 面辞职报告，申请辞去董事、董事长及董事会专门委员会等相关职务。应飚的辞职将在公司选举出新任 董事长后生效，辞职后他将不再担任公司任何职务。 所属行业：汽车–汽车零部件–底盘与发动机系统 智明达：股东拟询价转让503万股股份 6月12日，智 ...

Market Overview - On June 11, the Hang Seng Index rose by 204 points or 0.8%, closing at 24,366 points, while the Hang Seng Tech Index increased by 1.1% to 5,451 points[1] - The total market turnover reached over HKD 235.2 billion, with a net inflow of HKD 1.37 billion through the Hong Kong Stock Connect[1] - Key sectors leading the market included insurance, brokerage, gaming, oil, coal, non-ferrous metals, and engineering machinery, while biomedicine, food and beverage, and utilities lagged behind[1] Sector Performance - Major state-owned banks saw stock increases ranging from 1.1% to 2.5%[1] - Brokerage stocks benefited from merger rumors, with GF Securities (1776 HK) surging 6.2% and others like Huatai (6886 HK) and CITIC Securities (6066 HK) rising between 4.1% and 4.9%[1] - The gaming sector received a boost from new supportive measures, with Bilibili (9626 HK) climbing 9.9%[1] Economic Indicators - The automotive sector reported a wholesale volume of 2.686 million units in May, up 11.2% year-on-year and 3.7% month-on-month, with cumulative sales for the first five months increasing by 10.9%[3] - New energy vehicle sales surged by 44% year-on-year, achieving a penetration rate of 44%[3] - The global healthcare sector saw a 33.8% month-on-month increase in financing, totaling USD 4.85 billion in May, indicating a recovery in investment[3] Real Estate Insights - New home sales in 30 major cities fell to 1.42 million square meters, down 18.1% year-on-year and 33.3% month-on-month, indicating a significant decline in the real estate market[5] - The inventory-to-sales ratio for major cities rose to 85.4, compared to 83.6 last year, reflecting a slower inventory turnover[7] - Land transaction volumes dropped by 48.9% year-on-year, with a significant decline in the number of transactions[8] Strategic Recommendations - The current market strategy suggests waiting for fund rotation rather than chasing high-flying stocks, as the market lacks a clear leading sector[2] - Investors are advised to focus on undervalued sectors with high growth potential, particularly in the Hang Seng Tech Index, while maintaining a defensive stance in dividend-paying sectors[13]

Investment Rating - Investment Rating: Positive [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 3.36%, ranking 6th among 31 primary industries, outperforming the CSI 300 index, which decreased by 0.21% [5][17] - The valuation of the pharmaceutical and biotechnology industry as of June 6, 2025, is 28.24x (TTM, excluding negative values), up from 27.60x in the previous period, indicating an upward trend but still below the average [5][23] - Notable sub-industry performance includes chemical preparations and other biological products, with increases of 5.77% and 4.68% respectively, while offline pharmacies saw a decline of 1.15% [5][17] Industry Review - The report highlights three major investment opportunities: 1) Companies with dual-antibody/multi-antibody technology platforms that have differentiated target design capabilities and clinical advancement efficiency are likely to attract international giants [9] 2) Areas with unmet clinical needs, such as advanced liver cancer and non-small cell lung cancer, are promising for dual-antibody therapy development [9] 3) Potential license-out candidates, as domestic innovative pharmaceutical companies continue to engage in global collaborations [9] Important Industry News - CDE launched the "Star Plan" to encourage the development of pediatric anti-cancer drugs, addressing significant unmet clinical needs in this area [7][32] - Alcon's dry eye medication "Tryptyr" received FDA approval, marking it as the first of its kind globally [39] - Hansoh Pharmaceutical's third-generation EGFR-TKI "Amivantamab" was approved in the UK for first-line treatment of NSCLC, becoming the first domestically developed EGFR-TKI approved overseas [42] - BMS and BioNTech entered a collaboration for the dual-antibody candidate BNT327, with an upfront payment of $1.5 billion and potential milestone payments of $7.6 billion [51] Company Dynamics - Stone Pharmaceutical is negotiating three potential deals totaling $5 billion, involving several products including EGFR ADCs [49] - BMS's "Rotecip" was approved for treating lower-risk myelodysplastic syndromes, marking a significant innovation in this therapeutic area [45] - AbbVie’s JAK inhibitor "Upadacitinib" was approved for treating giant cell arteritis, becoming the first approved treatment for this condition in China [48]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2]. Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14]. - The pharmaceutical and biotechnology sector has shown a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18]. Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14]. - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15]. 2. Subsector Performance - The pharmaceutical sector's sub-indices all recorded gains, with the raw materials and blood products sectors leading with a 2.89% increase [7][22]. - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26]. 3. Recommended and Beneficiary Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihe Jiaye, among others [8]. - Beneficiary stocks identified are Shanhaishan, Yirui Technology, and Lianying Medical [27]. 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI applications in imaging and surgery [26]. - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29]. - **IVD Sector**: The report notes a 2.00% increase in the IVD sector, with a focus on AI-assisted diagnostics [30]. - **Blood Products**: The blood products sector is experiencing a 2.89% increase, with ongoing consolidation and product diversification [31]. - **Retail Pharmacy**: The offline pharmacy sector is expected to benefit from improved operational efficiencies through AI integration [34]. - **Healthcare Services**: The hospital sector has seen a 1.07% increase, with growth in specific medical fields like ophthalmology and reproductive health [36]. - **Traditional Chinese Medicine**: The sector is expected to recover as the impact of previous procurement policies diminishes [38]. - **CXO Sector**: The report indicates a positive outlook for the CXO sector, driven by increased demand for outsourcing in drug development [40].

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14] - The pharmaceutical and biotechnology sector has seen a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18] Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14] - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15] 2. Subsector Performance - The pharmaceutical and biotechnology sector has shown positive performance across all sub-sectors, with the raw materials and blood products sectors leading with a 2.89% increase [7][22] - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26] 3. Recommended and Benefiting Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihua Jiaye, among others [8] - Benefiting stocks from the current trends include Shanhaishan, Yirui Technology, and Lianying Medical [8][27] 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI integration in imaging and surgical applications [26] - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29] - **IVD Sector**: The in vitro diagnostics sector is anticipated to recover as AI technologies enhance diagnostic capabilities [30] - **Blood Products**: The blood products sector is experiencing stable demand, with a projected 10.9% increase in plasma collection in 2024 [31] - **Retail Pharmacy**: The retail pharmacy sector is expected to see improved performance as market conditions stabilize and AI technologies enhance operational efficiency [34] - **Healthcare Services**: The healthcare services sector is showing signs of recovery, particularly in ophthalmology and reproductive health services [36] - **Traditional Chinese Medicine**: The sector is expected to benefit from improved consumer sentiment and demand for high-quality OTC products [38] - **CXO Sector**: The CXO sector is entering an upward cycle as companies report improved order growth and performance [40]

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 阳光诺和(688621) 唐爱金 医药首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] STC007 二期临床数据读出，业务转型阶段把 握价值重估机遇 [Table_ReportDate] 2025 年 06 月 04 日 [Table_S 事件：2025ummar年y]5 月 29 日，公司公告全资子公司诺和晟泰自主研发的 STC007 注射液治疗腹部手术后的中、重度疼痛的 II 期临床试验达成预期目标。 点评： ➢ STC007 二期临床数据读出，具备较强的商业化潜力。 STC007 是诺和晟泰自主研发的化学 1 类新药，属于强效 KOR 激动剂， 与 KOR 受 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 阳光诺和(688621) 唐爱金 医药首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] STC007 二期临床数据读出，业务转型阶段把 握价值重估机遇 [Table_ReportDate] 2025 年 06 月 04 日 [Table_S 事件：2025ummar年y]5 月 29 日，公司公告全资子公司诺和晟泰自主研发的 STC007 注射液治疗腹部手术后的中、重度疼痛的 II 期临床试验达成预期目标。 点评： ➢ STC007 二期临床数据读出，具备较强的商业化潜力。 STC007 是诺和晟泰自主研发的化学 1 类新药，属于强效 KOR 激动剂， 与 KOR 受 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index increased by 3.08%, ranking third among 31 primary industries, outperforming the CSI 300 index which rose by 0.94% [5][17] - The report highlights the acceleration of internationalization of innovative drugs, with a focus on two main directions: the global multi-center clinical capabilities and differentiated technology platforms, as well as short-term opportunities driven by ASCO data [8][9] Industry Performance - The valuation of the pharmaceutical and biotechnology industry as of May 23, 2025, is a PE (TTM overall method, excluding negative values) of 27.60x, up from 26.77x in the previous period, indicating an upward trend but still below the average [22] - The top three sub-industries in terms of PE are vaccines (52.08x), hospitals (37.38x), and medical devices (33.40x), while the lowest valuation is in pharmaceutical distribution (15.18x) [22] Important Industry News - The CDE released guidelines for clinical trials of Alzheimer's disease drugs, aiming to provide technical standards for drug development [27] - AbbVie’s c-Met ADC "Teliso-V" received FDA approval, marking it as the first of its kind globally [28] - The report mentions significant collaborations, such as Pfizer's partnership with 3SBio for a PD-1/VEGF bispecific antibody, valued at over $6 billion [8][51] Company Dynamics - Hengrui Medicine officially listed on the Hong Kong Stock Exchange with an IPO price of HKD 44.05 per share, achieving a market capitalization of over HKD 290 billion [44][45] - The report notes that 35 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to CNY 1.336 billion during the reporting period [5]